Page editor		Section editor
	Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN AmitKulkarniMD		Travis Osterman, DO, MS, FAMIA Vanderbilt University Nashville, TN TravisOsterman LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

3 regimens on this page 3 variants on this page

Metastatic disease

Capmatinib monotherapy

back to top

FDA-recommended dose

Study	Years of enrollment	Evidence
Wolf et al. 2020 (GEOMETRY mono-1)	NR	Phase II (RT)

Continued indefinitely

GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains protocol PubMed NCT02414139

back to top

Study	Years of enrollment	Evidence
Paik et al. 2020 (VISION)	2016-2020	Phase II (RT)

Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.

Continued indefinitely

VISION: Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. link to original article contains verified protocol PubMed NCT02864992